Testing the drug datopotamab deruxtecan for breast cancer that has spread to the brain
Original title: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the drug has been tried in people but is still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called datopotamab deruxtecan in people whose breast cancer has spread to the brain.
Who this trial is for. This trial is for people with metastatic breast cancer that has spread to the brain. It tests a study drug called datopotamab deruxtecan, which is a type of antibody-drug conjugate.
Where it stands. There are no results yet. The study team is looking at how safe the drug is and how well it works in these patients. That answer is not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: This is one place where a new drug for brain metastases from breast cancer is being tested. If this sounds like your situation, you could ask your care team about it. They can tell you if a trial like this makes sense for you.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that you will be helped. It is not a promise of a cure. The trial team decides who can take part.
Source: ClinicalTrials.gov, August 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.